VCP171

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 555637

CAS#: 1018830-99-3

Description: VCP171 is an AR positive allosteric modulator. VCP171 elicited positive allosteric effects on the binding affinity of orthosteric agonists at both the rat and human A1 -receptors that showed clear probe dependence.


Price and Availability

Size
Price

Size
Price

Size
Price

VCP171 is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 555637
Name: VCP171
CAS#: 1018830-99-3
Chemical Formula: C18H12F3NOS
Exact Mass: 347.0592
Molecular Weight: 347.3552
Elemental Analysis: C, 62.24; H, 3.48; F, 16.41; N, 4.03; O, 4.61; S, 9.23


Synonym: VCP171; VCP-171; VCP 171;

IUPAC/Chemical Name: (2-Amino-4-(3-(trifluoromethyl)phenyl)thiophen-3-yl)(phenyl)methanone

InChi Key: HNHLVOBHWXLIGP-UHFFFAOYSA-N

InChi Code: InChI=1S/C18H12F3NOS/c19-18(20,21)13-8-4-7-12(9-13)14-10-24-17(22)15(14)16(23)11-5-2-1-3-6-11/h1-10H,22H2

SMILES Code: O=C(C1=C(N)SC=C1C2=CC=CC(C(F)(F)F)=C2)C3=CC=CC=C3


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>3 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
2934.99.90.01


References

1: Cooper SL, Soave M, Jörg M, Scammells PJ, Woolard J, Hill SJ. Probe dependence
of allosteric enhancers on the binding affinity of adenosine A(1) -receptor
agonists at rat and human A(1) -receptors measured using NanoBRET. Br J
Pharmacol. 2019 Apr;176(7):864-878. doi: 10.1111/bph.14575. Epub 2019 Mar 6.
PubMed PMID: 30644086; PubMed Central PMCID: PMC6433648.

2: Miao Y, Bhattarai A, Nguyen ATN, Christopoulos A, May LT. Structural Basis for
Binding of Allosteric Drug Leads in the Adenosine A(1) Receptor. Sci Rep. 2018
Nov 15;8(1):16836. doi: 10.1038/s41598-018-35266-x. PubMed PMID: 30442899; PubMed
Central PMCID: PMC6237911.

3: Nguyen AT, Vecchio EA, Thomas T, Nguyen TD, Aurelio L, Scammells PJ, White PJ,
Sexton PM, Gregory KJ, May LT, Christopoulos A. Role of the Second Extracellular
Loop of the Adenosine A1 Receptor on Allosteric Modulator Binding, Signaling, and
Cooperativity. Mol Pharmacol. 2016 Dec;90(6):715-725. Epub 2016 Sep 28. PubMed
PMID: 27683013.

4: Imlach WL, Bhola RF, May LT, Christopoulos A, Christie MJ. A Positive
Allosteric Modulator of the Adenosine A1 Receptor Selectively Inhibits Primary
Afferent Synaptic Transmission in a Neuropathic Pain Model. Mol Pharmacol. 2015
Sep;88(3):460-8. doi: 10.1124/mol.115.099499. Epub 2015 Jun 23. PubMed PMID:
26104547.